Search research articles
Contact Us
Filters
Showing results (71-80 of 92) with videos related to
Page
of 10
Sort By:
Annals of the Rheumatic Diseases
|
March 4, 2022
Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis
Philip J Mease, Atul A Deodhar, Désirée van der Heijde, et al.
Annals of the Rheumatic Diseases
|
October 9, 2023
Card9/neutrophil signalling axis promotes IL-17A-mediated ankylosing spondylitis
Holly L Rosenzweig, Emily E Vance, Kofi Asare-Konadu, et al.
Annals of the Rheumatic Diseases
|
December 1, 2011
Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo- controlled GO-RAISE study
Jürgen Braun, Xenofon Baraliakos, Kay-Geert A Hermann, et al.
The Journal of Rheumatology
|
July 2, 2009
Entheses and bones in spondyloarthritis: 2008 Annual Research and Education Meeting of the Spondyloarthritis Research and Therapy Network (SPARTAN)
Robert A Colbert, Atul A Deodhar, David Fox, et al.
Arthritis Care & Research
|
January 28, 2016
Observed Incidence of Uveitis Following Certolizumab Pegol Treatment in Patients With Axial Spondyloarthritis
M Rudwaleit, J T Rosenbaum, R Landewé, et al.
Annals of the Rheumatic Diseases
|
August 15, 2013
Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)
P J Mease, R Fleischmann, A A Deodhar, et al.
Arthritis Research & Therapy
|
May 4, 2019
Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data
A Deodhar, P J Mease, I B McInnes, et al.
The British Journal of Dermatology
|
April 8, 2021
The risk of malignancy in patients with secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow-up
M Lebwohl, A Deodhar, C E M Griffiths, et al.
Arthritis Care & Research
|
April 15, 2010
Denosumab-mediated increase in hand bone mineral density associated with decreased progression of bone erosion in rheumatoid arthritis patients
A Deodhar, R K Dore, D Mandel, et al.
ACR Open Rheumatology
|
May 1, 2020
Incidence of Uveitis in Secukinumab-treated Patients With Ankylosing Spondylitis: Pooled Data Analysis From Three Phase 3 Studies
Atul A Deodhar, Corine Miceli-Richard, Xenofon Baraliakos, et al.
Page
of 10
Search research articles
Search
Showing results (71-80 of 92) with videos related to
Sort By:
Page
of 10
Annals of the Rheumatic Diseases
|
March 4, 2022
Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis
Philip J Mease, Atul A Deodhar, Désirée van der Heijde, et al.
Annals of the Rheumatic Diseases
|
October 9, 2023
Card9/neutrophil signalling axis promotes IL-17A-mediated ankylosing spondylitis
Holly L Rosenzweig, Emily E Vance, Kofi Asare-Konadu, et al.
Annals of the Rheumatic Diseases
|
December 1, 2011
Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo- controlled GO-RAISE study
Jürgen Braun, Xenofon Baraliakos, Kay-Geert A Hermann, et al.
The Journal of Rheumatology
|
July 2, 2009
Entheses and bones in spondyloarthritis: 2008 Annual Research and Education Meeting of the Spondyloarthritis Research and Therapy Network (SPARTAN)
Robert A Colbert, Atul A Deodhar, David Fox, et al.
Arthritis Care & Research
|
January 28, 2016
Observed Incidence of Uveitis Following Certolizumab Pegol Treatment in Patients With Axial Spondyloarthritis
M Rudwaleit, J T Rosenbaum, R Landewé, et al.
Annals of the Rheumatic Diseases
|
August 15, 2013
Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)
P J Mease, R Fleischmann, A A Deodhar, et al.
Arthritis Research & Therapy
|
May 4, 2019
Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data
A Deodhar, P J Mease, I B McInnes, et al.
The British Journal of Dermatology
|
April 8, 2021
The risk of malignancy in patients with secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow-up
M Lebwohl, A Deodhar, C E M Griffiths, et al.
Arthritis Care & Research
|
April 15, 2010
Denosumab-mediated increase in hand bone mineral density associated with decreased progression of bone erosion in rheumatoid arthritis patients
A Deodhar, R K Dore, D Mandel, et al.
ACR Open Rheumatology
|
May 1, 2020
Incidence of Uveitis in Secukinumab-treated Patients With Ankylosing Spondylitis: Pooled Data Analysis From Three Phase 3 Studies
Atul A Deodhar, Corine Miceli-Richard, Xenofon Baraliakos, et al.
Page
of 10